CORMEDIX INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
CORMEDIX INC. (CRMD) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of 0.60% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-05
- CORMEDIX INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was 0.60%.
- CORMEDIX INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -0.10%.
- CORMEDIX INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2020 was 2.90%, a 53.23% decline from fiscal 2019.
- CORMEDIX INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2019 was 6.20%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.60% 10-K · filed 2026-03-05 | |
| 2024-12-31 | -0.10% 10-K · filed 2026-03-05 | |
| 2020-12-31 | 2.90% 10-K · filed 2021-03-30 | |
| 2019-12-31 | 6.20% 10-K · filed 2021-03-30 | |
| 2018-12-31 | 0.00% 10-K · filed 2020-03-16 | -0.30% 10-K · filed 2019-05-29 |
| 2017-12-31 | 0.10% 10-K · filed 2019-05-29 | |
| 2016-12-31 | 0.70% 10-K · filed 2018-03-19 | -0.70% 10-K · filed 2017-03-16 |
| 2015-12-31 | -0.10% 10-K · filed 2017-03-16 | |
| 2014-12-31 | -0.10% 10-K · filed 2017-03-16 | |
| 2013-12-31 | -0.60% 10-K · filed 2015-03-12 | 0.60% 10-K · filed 2014-03-31 |
| 2012-12-31 | 0.00% 10-K · filed 2014-03-31 | |
| 2011-12-31 | 3.90% 10-K/A · filed 2014-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |